drugset / Trial / NCT00255450

A Crossover Safety Study of Ferumoxytol Versus Placebo

NCT00255450

Phase 3 Completed 750 enrolled AMAG Pharmaceuticals, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.

Timeline

Start
2005-01
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent 510 mg Intravenous

Indications